From Fragmented Trials to a Structured Asia Network — Laboratoires Vivacy

How an 18-month mandate turned Laboratoires Vivacy's uneven history in Asia into a coordinated distribution network across nine markets — built to match the brand's premium standing in Europe.

The Challenge

A premium brand in Europe, an unstructured presence in Asia.

Founded in 2007, Laboratoires Vivacy built its reputation on rare ground for the category: full control from formulation to finished product, and close to two decades spent treating hyaluronic acid as a tool for tissue health rather than correction alone — work that positioned the brand among the pioneers of regenerative medical aesthetics in Europe.

Asia was the one region where the brand's premium status in Europe wasn't showing up in the numbers.

Asia told a different story. Over the years, the brand had tested the region through local distributor relationships pursued opportunistically rather than as part of one regional plan. The result was uneven regulatory progress, partners whose positioning didn't match the brand, and commercial performance well short of what Vivacy's quality and R&D pipeline warranted. Asia was the one region where the brand's premium status in Europe wasn't showing up in the numbers.

The mandate was direct: rebuild the region from scratch, market by market, in a way that finally matched the brand everywhere else.

The Approach

Six phases, run market by market, all at once

Each phase was sequenced deliberately — strategy before outreach, regulatory clarity before negotiation.

01 — Strategic roadmap. Prioritised Asia's markets by regulatory maturity, category readiness and commercial potential, sequencing entry rather than pursuing every market at once.

02 — Regulatory clarity. Mapped and clarified the registration pathway country by country — NMPA in China, MFDS in Korea, BPOM in Indonesia — ahead of any distributor conversation.

03 — Localized go-to-market. Built a go-to-market plan per priority market, adapted to local price positioning, channel structure and physician education — without diluting the brand's premium identity.

04 — Distributor sourcing. Identified and vetted distributors on fit, not just reach: brand alignment, category expertise and standing with the physicians who matter in each market.

05 — Negotiation & contracting. Negotiated distribution agreements structured to protect the brand's positioning, with clear, mutual performance expectations from day one.

06 — Launch execution. Coordinated regulatory clearance, distributor readiness and physician education into one sequenced rollout, market by market.

Built in Parallel: People, Not Just Paperwork

Contracts alone don't build a market — the people around the brand do. Alongside the commercial roadmap, we built a network of regional ambassadors and onboarded key opinion leaders market by market, engaging them early enough to support each launch rather than reacting to it afterwards.

By summer 2026, that groundwork came together at a dedicated partner event, bringing distributors from across the region together for the first time. The goal wasn't just alignment — it was culture: a multilayer, collaborative model where each market's specificities are respected locally, while everyone still pulls in the same direction regionally.

Where the Network Stands, Summer 2026

Laboratoires Vivacy's premium portfolio is live in seven markets, each with a vetted distributor, a cleared regulatory pathway and an engaged local physician network behind it:

The remaining priority markets are commercially ready — go-to-market plans, distributor relationships and launch materials are in place. Rollout there is now a matter of regulatory timing, not commercial readiness.

Why This Matters Now

Asia's aesthetics market is growing faster than it is getting easier to enter.

China remains the region's largest dermal filler market, Korea continues to set the clinical and aesthetic standard the rest of the region follows, and Indonesia — Southeast Asia's largest medical device market by import volume — is one of the region's most closely watched growth stories. Injectable treatments, fillers and botulinum toxin, are expected to stay the single largest category as demand rises across the region.

None of that growth is available for the taking, though. Each market runs on its own regulatory clock:

A brand that treats Asia as one market, or shortcuts the regulatory groundwork, tends to either stall for years or launch with the wrong partner. That's the gap a structured, market-by-market approach is built to close.

The Takeaway

What worked for Vivacy wasn't a single tactic — it was sequencing. Strategy before distributor outreach. Regulatory clarity before negotiation. Physician relationships built alongside contracts, not after them. And a regional culture stitched together deliberately, market by market, rather than left to chance.

That sequencing is what Asia Bio Bridge brings to biotech, pharma, medtech and cosmetics companies building — or rebuilding — their presence in Asia: a tailor-made path from strategic roadmap to a live, committed partner network, without the trial-and-error most brands go through first.

The Patient Perspective

Every regulatory filing and distributor agreement in this roadmap serves one outcome. Physicians — and the patients they treat — gain access in Asia to the same regenerative-grade products long available in Europe. Tools built around tissue health, not correction alone.

That's the promise behind the numbers: patients able to look, and feel, their best at any age.

---